In the next step, we calculated the TT-HBV risk in the eight infection stages for different HBV screening strategies, i.e., serologic HBsAg screening with and without anti-HBc testing, multiplex ID-NAT alone with either one of two widely used automated molecular test systems and the combined approach of using both serologic testing and NAT methods in either ID, MP6-, or MP16-NAT format. This evidence concerns the gene BRD2 and infection.